- Home
- RNTX vs INMB Comparison
RNTX vs INMB Comparison
Compare RNTX & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RNTX | INMB |
|---|---|---|
| Founded | 2001 | 2015 |
| Country | United States | United States |
| Employees | 11 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.0M | 34.3M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | RNTX | INMB |
|---|---|---|
| Price | $1.17 | $1.42 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 3 |
| Target Price | ★ $10.00 | $4.30 |
| AVG Volume (30 Days) | 83.9K | ★ 391.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $14,000.00 |
| Revenue This Year | N/A | $264.29 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.02 | $1.21 |
| 52 Week High | $2.27 | $11.64 |
Technical Indicators
Market Signals| Indicator | RNTX | INMB |
|---|---|---|
| Relative Strength Index (RSI) | 46.42 | 46.20 |
| Support Level | $1.06 | $1.21 |
| Resistance Level | $1.29 | $1.71 |
| Average True Range (ATR) | 0.10 | 0.12 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 38.46 | 41.28 |
Price Performance
Historical ComparisonAbout RNTX Rein Therapeutics Inc.
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.
About INMB INmune Bio Inc.
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.